Literature DB >> 10455259

Pharmacological characterization of extracellular acidification rate responses in human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells.

M C Coldwell1, I Boyfield, A M Brown, G Stemp, D N Middlemiss.   

Abstract

This study characterized pharmacologically the functional responses to agonists at human dopamine D2(long) (hD2), D3 (hD3) and D4.4 (hD4) receptors separately expressed in cloned cells using the cytosensor microphysiometer. Dopaminergic receptor agonists caused increases in extracellular acidification rate in adherent Chinese hamster ovary (CHO) clones expressing hD2, hD3 or hD4 receptors. Acidification rate responses to agonists in other cell lines expressing these receptors were smaller than those in adherent CHO cells. The time courses and maximum increases in acidification rate of the agonist responses in adherent CHO cells were different between the three dopamine receptor clones. Responses were blocked by pretreatment of cells with pertussis toxin or amiloride analogues. Most agonists had full intrinsic activity at each of the dopamine receptor subtypes, as compared to quinpirole, however both enantiomers of UH-232 and (-)3-PPP were partial agonists in this assay system. The functional potency of full agonists at each of the three receptors expressed in CHO cells was either higher than, or similar to, the apparent inhibition constants (Ki) determined in [125I]-iodosulpride competition binding studies. Functional selectivities of the agonists were less than radioligand binding selectivities. The rank orders of agonist potencies and selectivities were similar, but not identical, to the rank orders of radioligand binding affinities and selectivities. The dopamine receptor antagonists, iodosulpride and clozapine, had no effect on basal acidification rates but inhibited acidification responses in CHO cells to quinpirole in an apparently competitive manner. Antagonist potencies closely matched their radioligand binding affinities in these cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10455259      PMCID: PMC1566129          DOI: 10.1038/sj.bjp.0702657

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  35 in total

1.  The cytosensor microphysiometer: biological applications of silicon technology.

Authors:  H M McConnell; J C Owicki; J W Parce; D L Miller; G T Baxter; H G Wada; S Pitchford
Journal:  Science       Date:  1992-09-25       Impact factor: 47.728

2.  Shorter variants of the D3 dopamine receptor produced through various patterns of alternative splicing.

Authors:  B Giros; M P Martres; C Pilon; P Sokoloff; J C Schwartz
Journal:  Biochem Biophys Res Commun       Date:  1991-05-15       Impact factor: 3.575

Review 3.  Molecular biology of dopamine receptors.

Authors:  D R Sibley; F J Monsma
Journal:  Trends Pharmacol Sci       Date:  1992-02       Impact factor: 14.819

4.  Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.

Authors:  P Sokoloff; B Giros; M P Martres; M L Bouthenet; J C Schwartz
Journal:  Nature       Date:  1990-09-13       Impact factor: 49.962

5.  Continuous monitoring of receptor-mediated changes in the metabolic rates of living cells.

Authors:  J C Owicki; J W Parce; K M Kercso; G B Sigal; V C Muir; J C Venter; C M Fraser; H M McConnell
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

6.  Cloning of the cDNA and gene for a human D2 dopamine receptor.

Authors:  D K Grandy; M A Marchionni; H Makam; R E Stofko; M Alfano; L Frothingham; J B Fischer; K J Burke-Howie; J R Bunzow; A C Server
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

7.  Detection of cell-affecting agents with a silicon biosensor.

Authors:  J W Parce; J C Owicki; K M Kercso; G B Sigal; H G Wada; V C Muir; L J Bousse; K L Ross; B I Sikic; H M McConnell
Journal:  Science       Date:  1989-10-13       Impact factor: 47.728

8.  The major dopamine D2 receptor: molecular analysis of the human D2A subtype.

Authors:  L A Selbie; G Hayes; J Shine
Journal:  DNA       Date:  1989-11

9.  Two intracellular signaling pathways for the dopamine D3 receptor: opposite and synergistic interactions with cyclic AMP.

Authors:  N Griffon; C Pilon; F Sautel; J C Schwartz; P Sokoloff
Journal:  J Neurochem       Date:  1997-01       Impact factor: 5.372

10.  (+)-AJ 76 and (+)-UH 232: central stimulants acting as preferential dopamine autoreceptor antagonists.

Authors:  K Svensson; A M Johansson; T Magnusson; A Carlsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-11       Impact factor: 3.000

View more
  11 in total

Review 1.  The dopamine D4 receptor: biochemical and signalling properties.

Authors:  Pieter Rondou; Guy Haegeman; Kathleen Van Craenenbroeck
Journal:  Cell Mol Life Sci       Date:  2010-02-18       Impact factor: 9.261

2.  Functional coupling of the human dopamine D2 receptor with G alpha i1, G alpha i2, G alpha i3 and G alpha o G proteins: evidence for agonist regulation of G protein selectivity.

Authors:  Lucien Gazi; Sarah A Nickolls; Philip G Strange
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

Review 3.  The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence.

Authors:  Christian A Heidbreder; Eliot L Gardner; Zheng-Xiong Xi; Panayotis K Thanos; Manolo Mugnaini; Jim J Hagan; Charles R Ashby
Journal:  Brain Res Brain Res Rev       Date:  2005-07

4.  Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells.

Authors:  M C Coldwell; I Boyfield; T Brown; J J Hagan; D N Middlemiss
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

5.  Real-time analysis of dopamine: antagonist interactions at recombinant human D2long receptor upon modulation of its activation state.

Authors:  P J Pauwels; S Tardif; T Wurch; F C Colpaert
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

6.  Assays for enhanced activity of low efficacy partial agonists at the D(2) dopamine receptor.

Authors:  H Lin; S G N Saisch; P G Strange
Journal:  Br J Pharmacol       Date:  2006-08-21       Impact factor: 8.739

Review 7.  Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism.

Authors:  Georges Vauquelin; Sophie Bostoen; Patrick Vanderheyden; Philip Seeman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-14       Impact factor: 3.000

8.  Comparison of human recombinant adenosine A2B receptor function assessed by Fluo-3-AM fluorometry and microphysiometry.

Authors:  H Patel; R H P Porter; A M Palmer; M J Croucher
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

9.  The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats.

Authors:  Mark J Millan; Laetitia Seguin; Alain Gobert; Didier Cussac; Mauricette Brocco
Journal:  Psychopharmacology (Berl)       Date:  2004-02-19       Impact factor: 4.530

10.  Metabolic discrimination of select list agents by monitoring cellular responses in a multianalyte microphysiometer.

Authors:  Sven E Eklund; Roy G Thompson; Rachel M Snider; Clare K Carney; David W Wright; John Wikswo; David E Cliffel
Journal:  Sensors (Basel)       Date:  2009-03-23       Impact factor: 3.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.